Testimonials

"We engaged Cell&Gene Consulting Inc. to help us select a CDMO partner for our iPSC-derived cell therapy program. 

They quickly understood the scientific and operational nuances of our complex platform and helped translate those into technical and logistical requirements that could be communicated to potential partners. 

They took the ball and ran with it: they generated a detailed RFP that was submitted to 14 CDMOs, led all corresponding interviews and delivered results using a precise methodology relying on data and not just gut feeling. 

Their structured approach to evaluating service providers, from capability mapping to site audits and negotiation support, played a key role in helping us identify the right long-term partner. Their thoughtful guidance, CMC understanding and strategic perspective gave us the clarity we needed to make a well-informed decision."

"It is my honor to strongly recommend Arnaud and his array of specialty sub-contractors at Cell&Gene Consulting Inc. for your consulting needs. 

As the Chief Technology Officer at Triumvira Immunologics, I have had the opportunity to work directly with Arnaud as CDMO project director, a co-worker, and in a consulting capacity. 

While I’ve worked with many people over the course of my 30+ years in the field of cell & gene therapy, it is Arnaud’s deep understanding and keen perception of the field that impresses me the most. He is effective at analyzing the complex situations that face the field, providing  valuable perspectives, and offering an array of insightful solutions to fit a client’s needs. 

Arnaud & his consulting team offer comprehensive and integrated approaches for early to mid-stage cell & gene therapy development including strategic planning, IND/CTA preparation, CMC readiness, manufacturing technology, safety and risk assessment, development planning, and technology transfer to help clients navigate the complex and ever-changing landscape of cell and gene therapy." 

“We have worked with Cell&Gene Consulting Inc. for approximately 15 months. 

They have expertise in cell therapy manufacturing with a particular focus on the Lonza Cocoon. 

They have consistently demonstrated a deep understanding of the complex and highly regulated processes involved in cell therapy production, ensuring the highest standards of quality, safety, and efficiency. 

Beyond technical skills, their Principal Arnaud is a true team player and always responds in a timely manner as an external contractor.”

"Working with Cell&Gene Consulting Inc. was an excellent experience for Galapagos. 

They brought a rare combination of strategic insight, operational focus, and deep cell therapy industry knowledge that made an immediate impact across our teams. Their ability to analyze, offer clear direction, and drive results was instrumental in moving several key initiatives forward. 

We highly recommend them to any organization seeking smart, effective, and agile consulting support for complex challenges in the cell therapy space."

“I brought Cell&Gene Consulting Inc. on board to help us navigate the complex CMC landscape for our cell and gene therapy program, and their impact was immediate. They conducted a thorough assessment of our current state and then built a comprehensive and realistic CMC roadmap tailored to our development goals, complete with suggested timelines aligned to our overall project milestones. 

They walked us through things we did not even know we needed to think about.

What set Cell&Gene Consulting Inc. apart was not just their deep technical and industry knowledge, but their ability to simplify complexity and present actionable options. They highlighted qualified partners we could work with and helped make strategic introductions. Their insights were key to helping us plan out our program with confidence and they were highly communicative throughout the process. 

I would recommend them with confidence to any company looking to build or strengthen their CMC strategy in the cell and gene therapy space.”

“Cell&Gene Consulting Inc. have been an exceptional asset to both me and my team over the last 12 months, and it has been a pleasure collaborating with them over the past year. Their deep expertise in cell therapy CMC development has been invaluable, significantly strengthening our internal capabilities and providing the additional bandwidth needed to drive priority CMC and PD-related projects under tight deadlines.

Throughout our work together, they have consistently delivered impactful results, including the creation of a comprehensive COGS analysis framework, support in evaluating alternative technologies for implementation in our processes, and assistance in drafting key CMC-related documents for the development and lifecycle management of allogeneic cell therapy products. 

Their contributions have been instrumental in advancing our goals within Tech Ops with precision and efficiency.”